GB855163A - Improvements in or relating to stabilized chymotrypsin solution - Google Patents
Improvements in or relating to stabilized chymotrypsin solutionInfo
- Publication number
- GB855163A GB855163A GB20943/58A GB2094358A GB855163A GB 855163 A GB855163 A GB 855163A GB 20943/58 A GB20943/58 A GB 20943/58A GB 2094358 A GB2094358 A GB 2094358A GB 855163 A GB855163 A GB 855163A
- Authority
- GB
- United Kingdom
- Prior art keywords
- chymotrypsin
- per
- concentration
- water
- calcium acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108090000317 Chymotrypsin Proteins 0.000 title abstract 9
- 229960002376 chymotrypsin Drugs 0.000 title abstract 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 6
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 abstract 4
- 239000001639 calcium acetate Substances 0.000 abstract 4
- 229960005147 calcium acetate Drugs 0.000 abstract 4
- 235000011092 calcium acetate Nutrition 0.000 abstract 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 2
- 231100000252 nontoxic Toxicity 0.000 abstract 2
- 230000003000 nontoxic effect Effects 0.000 abstract 2
- 238000007911 parenteral administration Methods 0.000 abstract 2
- 239000003755 preservative agent Substances 0.000 abstract 2
- 230000002335 preservative effect Effects 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 abstract 2
- 238000011200 topical administration Methods 0.000 abstract 2
- 230000000699 topical effect Effects 0.000 abstract 2
- 150000007513 acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
A stabilized aqueous solution of chymotrypsin for topical or parenteral administration contains between 0,05 and 1,2% by weight of calcium acetate, has a pH of 3,5 to 6,0 and a concentration of chymotrypsin of between 1 and 10 mg. per ml of water. A preferred solution contains 0,15 to 0,25% of calcium acetate, has a pH at 3,7 to 4,3 and a chymotrypsin concentration of 4 to 6 mg per ml of water. The chymotrypsin is preferably pure and in the alpha-form. It is preferred to adjust the pH with acetic acid but other non-toxic acids such as hydrochloric acid may be used. A preservative such as merthiolate or glycerol may also be present. Specification 727,611 is referred to.ALSO:A stabilized aqueous solution of chymotrypsin for topical or parenteral administration contains between 0,05 and 1,2% by weight of calcium acetate, has a pH of 3,5 to 6,0 and a concentration of chymotrypsin of between 1 and 10 mg. per ml of water. A preferred solution contains 0,15 to 0,25% of calcium acetate, has a pH of 3,7 to 4,3 and a chymotrypsin concentration of 4 to 6 mg. per ml of water. The chymotrypsin is preferably pure and in the alpha form. The pH may be adjusted by a non-toxic acid such as hydrochloric but acetic acid is preferred. A preservative such as merthiolate or glycerol may also be present. Specification 727,611 is referred to.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US855163XA | 1957-07-05 | 1957-07-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB855163A true GB855163A (en) | 1960-11-30 |
Family
ID=22192128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB20943/58A Expired GB855163A (en) | 1957-07-05 | 1958-06-30 | Improvements in or relating to stabilized chymotrypsin solution |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB855163A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0968707A3 (en) * | 1998-07-03 | 2003-08-13 | Beiersdorf Aktiengesellschaft | Compositions against acne and inflamed comedones containing serine proteases and one or more calcium salts |
-
1958
- 1958-06-30 GB GB20943/58A patent/GB855163A/en not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0968707A3 (en) * | 1998-07-03 | 2003-08-13 | Beiersdorf Aktiengesellschaft | Compositions against acne and inflamed comedones containing serine proteases and one or more calcium salts |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS55153712A (en) | Insulin pharmaceutical preparation and its production | |
| GB911185A (en) | Electrically conductive compositions | |
| AU576204B2 (en) | Aqueous, injectable solutions of cis-platimum | |
| KR930000096A (en) | Formulation | |
| BG48923A3 (en) | METHOD OF OBTAINING OXYTETRACYCLINE INJECTION SOLUTION | |
| GB855163A (en) | Improvements in or relating to stabilized chymotrypsin solution | |
| SE327779B (en) | ||
| KR880002507A (en) | Lyophilized Pharmaceutical Compositions of Phenylquinoline Carboxylic Acid | |
| ES349148A1 (en) | Method of,and formulations for,introducing alkoxybenzamides into the systemic circulatory system | |
| ES395433A1 (en) | Stable aqueous pyritinol solutions | |
| Lowenthal et al. | The inhibition of hyaluronidase by sodium salicylate and its possible metabolites | |
| GB1431709A (en) | Lysozyme derivatives | |
| GB866423A (en) | Improvements in or relating to chymotrypsin solutions | |
| GB1240638A (en) | Racemisation of alanine derivatives | |
| JPS5531028A (en) | Injection | |
| GB823242A (en) | Therapeutic compositions containing choline salts of dialkyl xanthines | |
| GB929642A (en) | Sweetening agent | |
| JPS5664772A (en) | Storage of food | |
| GB619065A (en) | Improvements in or relating to a method of stabilising an aqueous solution of ascorbic acid (vitamin c) | |
| GB1389859A (en) | Salts of fluorinated amino acid with optically active acids or bases | |
| GB713720A (en) | Improvements in or relating to the preparation of stabilized liquid catalase | |
| GB875609A (en) | Improvements in or relating to diagnostic compositions | |
| GRINEVA et al. | TRANSPORT OF H 2 O 18 INTO MAIZE LEAVES UNDER VARIOUS CONDITIONS OF ANAEROBIOSIS,(IN RUSSIAN) | |
| JPS5231020A (en) | Process for preparation of lysine hydrate crystal | |
| GB1106076A (en) | Stable, aqueous insulin solutions |